<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478686</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1003</org_study_id>
    <nct_id>NCT00478686</nct_id>
  </id_info>
  <brief_title>Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine</brief_title>
  <official_title>A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myrexis Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this laboratory research study is to identify possible differences in a gene
      among patients with breast cancer that cannot be treated by surgery. Researchers want to find
      out if differences in this gene may increase the risk of side effects from capecitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you agree to take part in this study, 1 blood sample (about 2 tablespoons) will be drawn
      for use in genetic research.

      If you are unable to provide a blood sample, researchers will collect leftover tissue samples
      from your previously collected tumor tissue (from the time of the breast cancer diagnosis).
      The tumor samples will be used for genetic research.

      After the blood draw or tissue collection, your participation in this study will be over.

      The blood samples for the genetic research will be stored at Myriad Laboratories. Before your
      blood and/or tissue is sent to Myriad Laboratories for banking, your name and any personal
      identifying information will be coded to protect your privacy. M. D. Anderson will not have
      oversight of any leftover tissue and/or blood that will be banked by Myriad Laboratories for
      additional research.

      This is an investigational study. Up to 210 patients will take part in this study. All will
      be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2007</start_date>
  <completion_date type="Actual">May 2, 2017</completion_date>
  <primary_completion_date type="Actual">May 2, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DPYD variants in patients</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">102</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Severe Toxicity</arm_group_label>
    <description>Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Limiting Toxicity</arm_group_label>
    <description>Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low/No Toxicity</arm_group_label>
    <description>Patients who have experienced low/no toxicity (none or only side effects at grade 1 &amp; 2) with capecitabine chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>5 to 7.5 milliliter (mL) Blood Sample</description>
    <arm_group_label>Severe Toxicity</arm_group_label>
    <arm_group_label>Dose-Limiting Toxicity</arm_group_label>
    <arm_group_label>Low/No Toxicity</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5 to 7.5 milliliter (mL) sample of blood. Alternatively, DNA will be extracted from 10um
      slices of formalin-fixed paraffin-embedded tissue from previously collected tumor tissue
      (from the time of the breast cancer diagnosis).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breast cancer who experienced toxicity/side effects related to capecitabine
        chemotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be registered for protocol ID 01-580 and only patients who were
             randomized to receive capecitabine will be included in the study.

          2. Patients must sign an informed consent for this protocol.

        Exclusion Criteria:

        1) There are no exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Valero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2007</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Dihydropyrimidine Dehydrogenase</keyword>
  <keyword>DPYD</keyword>
  <keyword>DPYD Variants</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Xeloda</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

